Organigram Holdings Inc., a leading licensed producer of cannabis, is pleased to announce today that it has expanded its global footprint by entering into a supply agreement (“the Agreement”) to provide dried Medical Cannabis flower to 4C LABS, a rapidly scaling healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution, and clinical development of cannabis-based products for human health in the United Kingdom.
Under the terms of the Agreement, the Company expects to supply approximately 600 kilograms of high-quality, indoor-grown dried flower product to 4C LABS within the first year of the Agreement, and grant 4C LABS strain exclusivity within the geographical boundaries of the United Kingdom & Channel Islands for as long as minimum purchase commitments are satisfied.
“Medical Cannabis has been legal in the UK since 2018. However, due to significant energy cost premiums compared to Canada, access to consistent, high-quality products in this market is limited, making importing Medical Cannabis an attractive option for this growing market,” says Beena Goldenberg, Chief Executive Officer of Organigram. “We are excited to partner with 4C LABS to increase access to Medical Cannabis for UK Medical Cannabis patients.”
“4C LABS is focused on delivering a value proposition to UK patients, 4C LABS provides top quality products, industry leading pricing, best in class customer service and a robust supply chain,” says Greg Dobbin, Chief Executive Officer of 4C LABS. “We are excited to bring Organigram products to the UK & Channel Islands.”
Activities under the Agreement are subject to compliance with all applicable laws, including receipt from time to time of all requisite approvals from Health Canada, the UK Medicines and Healthcare Products Regulatory Agency, and any other applicable regulatory authorities.
About Organigram Holdings Inc.
Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
About 4C Labs
4C LABS is a healthcare, technology and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products (CBMP’s) for human health. 4C LABS is committed to advancing scientific research, as well as enabling the regulation, distribution and prescribing of CBPM’s in the UK and Channel Islands. Its work with leading scientists, specialist physicians and pharmacists is underpinned with disruptive technologies that are driving an approach to treatment that prioritizes patients and evidence over stigma. 4C LABS works closely with Drug Science, the Cannabis Industry Council (CIC), The Medicines and Healthcare Products Regulatory Agency (MHRA) and the Care Quality Commission (CQC) to catalyze safe, regulated change in the medical landscape. 4C LABS is fully licensed in the UK with MS WDA, Schedule 1 Narcotics and Production licenses.
